Tag Archives: Sarepta

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments  Sarepta Therapeutics Sarepta to Report Q2 Earnings: What’s in Store for the Stock?  Nasdaq Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results  Yahoo Finance Sarepta Therapeutics Earnings Preview: Analysts Expect $1.01 EPS  AInvest Sarepta Therapeutics, Inc. SEC 10-Q Report  TradingView Source link

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy  Fierce Pharma Trump drove firing of FDA official  Politico Are we sure Vinay Prasad’s ouster is positive for biotech?  statnews.com FDA’s Prasad Exits Following Political Backlash Over Sarepta  Bloomberg.com FDA’s top vaccine official leaves post after less than four months  The Guardian Source link

Stocks held steady after the Federal Open Market Committee kept interest rates unchanged at its July meeting. The decision to hold the target range for the federal-funds rate between 4.25% and 4.5% was widely expected by market participants. Odds of at least a quarter-point cut through the FOMC’s next meeting in September were at 59.7% heading into the decision. Federal …

FDA’s Prasad Exits Following Political Backlash Over Sarepta  Bloomberg.com Vinay Prasad, a powerful FDA official, departs after controversy over rare disease drug  statnews.com FDA vaccine chief leaving agency after less than 3 months  AP News FDA’s top vaccine official leaves post after less than four months  The Guardian U.S. FDA’s chief medical and science officer Prasad departs agency  CNBC Source link

By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy’s withdrawal from the market. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a …

SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More Movers  Barron’s Stocks making the biggest moves premarket: Novo Nordisk, Whirlpool, Sarepta Therapeutics and more  CNBC Procter & Gamble, Sarepta Therapeutics, Cadence Design Systems  TradingView Source link

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. In a sharp reversal, the Food and Drug Administration on …

Investing.com — The U.S. Food and Drug Administration has recommended lifting the voluntary hold on Sarepta Therapeutics (NASDAQ:SRPT)’ gene therapy Elevidys for ambulatory patients with Duchenne Muscular Dystrophy (DMD). The FDA concluded that the death of an 8-year-old boy was unrelated to the gene therapy product itself, allowing ambulatory patients to once again receive the treatment. However, the voluntary hold …

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS  Sarepta Therapeutics The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear  statnews.com FDA probes death of patient on Sarepta’s Elevidys, partner Roche says death unrelated to therapy  Reuters ‘We will crack gene therapy’: Elevidys fallout doesn’t dent Roche’s hopes for modality  Fierce Biotech FDA weighs new study requirements for Sarepta to confirm …

Jennifer Hill Blair recognized the Cincinnati number on her buzzing phone and slipped out of the school meeting, excited to finally learn when her son Cayse would receive a therapy she believed would change his life. Blair, a second-grade teacher in southern Mississippi, and her husband had been fighting the state insurer since April, calling senators and representatives to lobby …